ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

GLUE Monte Rosa Therapeutics Inc

3,83
-0,18 (-4,49%)
15 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Monte Rosa Therapeutics Inc GLUE NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,18 -4,49% 3,83 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,99 3,71 4,11 3,83 4,01
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
14.6.202414:45GLOBEMonte Rosa Therapeutics Presents Preclinical Data at EULAR..
13.6.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.6.202422:00EDGAR2Form 8-K - Current report
05.6.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.6.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.6.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.6.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.6.202422:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
05.6.202422:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
30.5.202413:18EDGAR2Form 8-K - Current report
30.5.202413:00GLOBEMonte Rosa Therapeutics Announces Leadership Team Promotions
21.5.202413:00GLOBEMonte Rosa Therapeutics Presents Preclinical Data at..
16.5.202422:06EDGAR2Form 8-K - Current report
16.5.202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16.5.202413:00GLOBEMonte Rosa Therapeutics Announces Pricing of $100 Million..
15.5.202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15.5.202422:01GLOBEMonte Rosa Therapeutics Announces Proposed Public Offering..
09.5.202413:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.5.202413:05EDGAR2Form 8-K - Current report
09.5.202413:00GLOBEMonte Rosa Therapeutics Announces First Quarter 2024..
02.5.202422:01GLOBEMonte Rosa Therapeutics Announces the Departure of Owen..
14.3.202412:00GLOBEMonte Rosa Therapeutics Announces Fourth Quarter and Full..
11.3.202412:00GLOBEMonte Rosa Therapeutics Announces Initiation of IND Enabling..
31.1.202413:00GLOBEMonte Rosa Therapeutics to Participate in Upcoming Investor..
08.1.202413:47EDGAR2Form 8-K - Current report
08.1.202413:15GLOBEMonte Rosa Therapeutics Provides Corporate Update and Key..
04.1.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202413:00GLOBEMonte Rosa Therapeutics to Present at the 42nd Annual J.P...
21.11.202313:00GLOBEMonte Rosa Therapeutics to Present at Piper Sandler..
09.11.202313:27EDGAR2Form 8-K - Current report
09.11.202313:00GLOBEMonte Rosa Therapeutics Announces Third Quarter 2023..
07.11.202316:00GLOBEMonte Rosa Therapeutics Presents Preclinical Data at ACR..
27.10.202313:00GLOBEMonte Rosa Therapeutics to Participate in Upcoming Investor..
26.10.202323:01EDGAR2Form 8-K - Current report
26.10.202322:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26.10.202322:30GLOBEMonte Rosa Therapeutics Announces $25 Million Registered..
17.10.202313:55EDGAR2Form 8-K - Current report
17.10.202313:00GLOBEMonte Rosa Therapeutics Announces Interim PK/PD and Clinical..
18.8.202322:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
15.8.202323:16EDGAR2Form 144 - Report of proposed sale of securities
10.8.202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202313:19EDGAR2Form 8-K - Current report
10.8.202313:15GLOBEMonte Rosa Therapeutics Announces Second Quarter 2023..
26.7.202313:53EDGAR2Form 8-K - Current report
26.7.202313:30GLOBEMonte Rosa Therapeutics Appoints Dr. Anthony M. Manning to..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock